Chinese Peptide Company

Click Here To EMAIL INQUIRY
Contact: Nancy Chen
Web: http://www.chinesepeptide.com
E-Mail:
Address: No. 69, 12 Street, Economic, And Technological Development, Zone, Hangzhou, China
Phone: +86-(571)-86737011 | Fax: +86-(571)-86737013 | Map/Directions >>

Profile: Chinese Peptide Company specializes in the production of peptides for use in the medical field. Our products include obestatin, tamra, biotin-obestatin, fam-obestatin, parathyroid hormone, thymosin b4, thymosin alpha, somatostatin, octreotide, secretin-porcine, glucagon and ghrelin. We provide somatostatin peptides that inhibit the release of growth hormone, thyrotropin stimulating hormone & prolactin releasing hormone from the pituitary, that inhibits release of calcitonin, insulin, glucagon, pancreatic polypeptide, gastrin releasing peptide and CCK. Our glucagon shows a strong insulinotropic effect that is mediated by receptors expressed in the pancreatic beta cells. The octreotide is a synthetic analog of somatostatin. It is three times more potent than the native hormone in inhibiting the secretion of growth hormone.

16 Products/Services (Click for related suppliers)

• Amphetamine Enzyme Immunoassay Test (FDA Code: DKZ / 862.3100)

An amphetamine test system is a device intended to measure amphetamine, a central nervous system stimulating drug, in plasma and urine. Measurements obtained by this device are used in the diagnosis and treatment of amphetamine use or overdose and in monitoring levels of amphetamine to ensure appropriate therapy.

• Barbiturate Enzyme Immunoassay Test (FDA Code: DIS / 862.3150)

A barbiturate test system is a device intended to measure barbiturates, a class of hypnotic and sedative drugs, in serum, urine, and gastric contents. Measurements obtained by this device are used in the diagnosis and treatment of barbiturate use or overdose and in monitoring levels of barbiturate to ensure appropriate therapy.

• Benzodiazepine Enzyme Immunoassay Test (FDA Code: JXM / 862.3170)

A benzodiazepine test system is a device intended to measure any of the benzodiazepine compounds, sedative and hypnotic drugs, in blood, plasma, and urine. The benzodiazepine compounds include chlordiazepoxide, diazepam, oxazepam, chlorzepate, flurazepam, and nitrazepam. Measurements obtained by this device are used in the diagnosis and treatment of benzodiazepine use or overdose and in monitoring levels of benzodiazepines to ensure appropriate therapy.

• Cannabinoids Enzyme Immunoassay Test (FDA Code: LDJ / 862.3870)

A cannabinoid test system is a device intended to measure any of the cannabinoids, hallucinogenic compounds endogenous to marihuana, in serum, plasma, saliva, and urine. Cannabinoid compounds includedelta -9-tetrahydrocannabinol, cannabidiol, cannabinol, and cannabichromene. Measurements obtained by this device are used in the diagnosis and treatment of cannabinoid use or abuse and in monitoring levels of cannabinoids during clinical investigational use.

• Cocaine and Cocaine Metabolites Enzyme Immunoassay Test (FDA Code: DIO / 862.3250)

A cocaine and cocaine metabolite test system is a device intended to measure cocaine and a cocaine metabolite (benzoylecgonine) in serum, plasma, and urine. Measurements obtained by this device are used in the diagnosis and treatment of cocaine use or overdose.

• Metamphetamine Thin Layer Chromatography Test (FDA Code: DJC / 862.3610)

A methamphetamine test system is a device intended to measure methamphetamine, a central nervous system stimulating drug, in serum, plasma, and urine. Measurements obtained by this device are used in the diagnosis and treatment of methamphetamine use or overdose.

• Methadone Enzyme Immunoassay Test (FDA Code: DJR / 862.3620)

A methadone test system is a device intended to measure methadone, an addictive narcotic pain-relieving drug, in serum and urine. Measurements obtained by this device are used in the diagnosis and treatment of methadone use or overdose and to determine compliance with regulations in methadone maintenance treatment.

• Methadone Gas Chromatography Test (FDA Code: DMB / 862.3620)

• Methamphetamine Gas Chromatography Test (FDA Code: LAF / 862.3610)

• Opiates Enzyme Immunoassay Test (FDA Code: DJG / 862.3650)

An opiate test system is a device intended to measure any of the addictive narcotic pain-relieving opiate drugs in blood, serum, urine, gastric contents, and saliva. An opiate is any natural or synthetic drug that has morphine-like pharmocological actions. The opiates include drugs such as morphine, morphine glucoronide, heroin, codeine, nalorphine, and meperedine. Measurements obtained by this device are used in the diagnosis and treatment of opiate use or overdose and in monitoring the levels of opiate administration to ensure appropriate therapy.

• Parathyroid Hormone Radioimmunoassay Test (FDA Code: CEW / 862.1545)

A parathyroid hormone test system is a device intended to measure the levels of parathyroid hormone in serum and plasma. Measurements of parathyroid hormone levels are used in the differential diagnosis of hypercalcemia (abnormally high levels of calcium in the blood) and hypocalcemia (abnormally low levels of calcium in the blood) resulting from disorders of calcium metabolism.

• Peptide Coupling Reagents

• Peptides

• Phencyclidine Enzyme Immunoassay (FDA Code: LCM)

• Propoxyphene Enzyme Immunoassay (FDA Code: JXN / 862.3700)

A propoxyphene test system is a device intended to measure propoxyphene, a pain-relieving drug, in serum, plasma, and urine. Measurements obtained by this device are used in the diagnosis and treatment of propoxyphene use or overdose or in monitoring levels of propoxyphene to ensure appropriate therapy.

• Tricyclic Antidepressant Drugs Radioimmunoassay Test (FDA Code: LFG / 862.3910)

A tricyclic antidepressant drugs test system is a device intended to measure any of the tricyclic antidepressant drugs in serum. The tricyclic antidepressant drugs include imipramine, desipramine, amitriptyline, nortriptyline, protriptyline, and doxepin. Measurements obtained by this device are used in the diagnosis and treatment of chronic depression to ensure appropriate therapy.